Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATYR NASDAQ:DTIL NASDAQ:HLVX NASDAQ:LPTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRaTyr Pharma$1.02+2.0%$3.11$0.68▼$7.29$97.99M0.7913.30 million shs6.35 million shsDTILPrecision BioSciences$6.90+3.9%$5.14$3.61▼$9.20$78.27M1.72123,263 shs417,502 shsHLVXHilleVax$2.09$2.09$1.34▼$2.17$104.79M0.77838,767 shsN/ALPTXLeap Therapeutics$0.55-3.7%$0.39$0.22▼$4.79$23.74M-0.057.86 million shs981,959 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRaTyr Pharma+2.00%-3.77%-0.49%-82.97%-62.50%DTILPrecision BioSciences+3.92%+22.78%+52.32%+49.67%-23.42%HLVXHilleVax0.00%0.00%-0.48%+1.46%+14.84%LPTXLeap Therapeutics-3.74%-13.63%+76.25%+60.32%-77.02%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRaTyr Pharma$1.02+2.0%$3.11$0.68▼$7.29$97.99M0.7913.30 million shs6.35 million shsDTILPrecision BioSciences$6.90+3.9%$5.14$3.61▼$9.20$78.27M1.72123,263 shs417,502 shsHLVXHilleVax$2.09$2.09$1.34▼$2.17$104.79M0.77838,767 shsN/ALPTXLeap Therapeutics$0.55-3.7%$0.39$0.22▼$4.79$23.74M-0.057.86 million shs981,959 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRaTyr Pharma+2.00%-3.77%-0.49%-82.97%-62.50%DTILPrecision BioSciences+3.92%+22.78%+52.32%+49.67%-23.42%HLVXHilleVax0.00%0.00%-0.48%+1.46%+14.84%LPTXLeap Therapeutics-3.74%-13.63%+76.25%+60.32%-77.02%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATYRaTyr Pharma 2.00Hold$23.252,179.41% UpsideDTILPrecision BioSciences 2.33Hold$47.00581.16% UpsideHLVXHilleVax 2.00Hold$2.00-4.31% DownsideLPTXLeap Therapeutics 1.75Reduce$3.38511.97% UpsideCurrent Analyst Ratings BreakdownLatest LPTX, DTIL, HLVX, and ATYR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ATYRaTyr PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025DTILPrecision BioSciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025LPTXLeap TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ATYRaTyr PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025DTILPrecision BioSciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025LPTXLeap TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/15/2025ATYRaTyr PharmaJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/15/2025ATYRaTyr PharmaLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/15/2025ATYRaTyr PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight9/15/2025ATYRaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral9/15/2025ATYRaTyr PharmaLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform(Data available from 10/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATYRaTyr Pharma$230K434.56N/AN/A$0.83 per share1.23DTILPrecision BioSciences$68.70M1.18N/AN/A$6.87 per share1.00HLVXHilleVaxN/AN/AN/AN/A$3.10 per shareN/ALPTXLeap TherapeuticsN/AN/AN/AN/A$0.91 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATYRaTyr Pharma-$64.02M-$0.80N/AN/AN/AN/A-93.69%-68.83%11/6/2025 (Estimated)DTILPrecision BioSciences$7.17M-$8.81N/AN/AN/A-6,205.79%-176.47%-69.05%11/3/2025 (Estimated)HLVXHilleVax-$147.27M-$1.43N/AN/AN/AN/A-34.29%-28.50%11/6/2025 (Estimated)LPTXLeap Therapeutics-$67.56M-$1.58N/AN/AN/AN/A-237.65%-155.38%11/12/2025 (Estimated)Latest LPTX, DTIL, HLVX, and ATYR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025LPTXLeap Therapeutics-$0.24N/AN/AN/AN/AN/A11/6/2025Q3 2025ATYRaTyr Pharma-$0.19N/AN/AN/AN/AN/A11/3/2025Q3 2025DTILPrecision BioSciences-$0.31N/AN/AN/AN/AN/A8/14/2025Q2 2025LPTXLeap Therapeutics-$0.29-$0.40-$0.11-$0.40N/AN/A8/7/2025Q2 2025ATYRaTyr Pharma-$0.18-$0.22-$0.04-$0.22N/AN/A8/7/2025Q2 2025DTILPrecision BioSciences-$0.09-$2.13-$2.04-$2.13$6.27 million$0.02 million8/6/2025Q2 2025HLVXHilleVax-$0.14-$0.11+$0.03-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATYRaTyr PharmaN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/AHLVXHilleVaxN/AN/AN/AN/AN/ALPTXLeap TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATYRaTyr Pharma0.015.635.63DTILPrecision BioSciences0.665.185.18HLVXHilleVaxN/A26.3926.39LPTXLeap TherapeuticsN/A1.341.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATYRaTyr Pharma61.72%DTILPrecision BioSciences37.99%HLVXHilleVax86.42%LPTXLeap Therapeutics30.46%Insider OwnershipCompanyInsider OwnershipATYRaTyr Pharma3.70%DTILPrecision BioSciences4.50%HLVXHilleVax24.90%LPTXLeap Therapeutics7.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATYRaTyr Pharma5397.99 million94.36 millionOptionableDTILPrecision BioSciences20011.79 million11.26 millionNo DataHLVXHilleVax2050.14 million37.66 millionNot OptionableLPTXLeap Therapeutics4041.44 million38.33 millionOptionableLPTX, DTIL, HLVX, and ATYR HeadlinesRecent News About These CompaniesWall Street Zen Downgrades Leap Therapeutics (NASDAQ:LPTX) to Strong Sell42 minutes ago | americanbankingnews.comLeap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury StrategyOctober 9, 2025 | finance.yahoo.comLeap Therapeutics Announces $58.88M Private PlacementOctober 8, 2025 | msn.comLeap Therapeutics stock soars after securing $58.9M investmentOctober 6, 2025 | investing.comLeap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury StrategyOctober 6, 2025 | prnewswire.comLeap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025September 25, 2025 | prnewswire.comLeap Therapeutics Reports Q2 2025 Financial ResultsAugust 15, 2025 | msn.comLeap Therapeutics, Inc.: Leap Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 14, 2025 | finanznachrichten.deLeap Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 14, 2025 | prnewswire.comLeap Therapeutics, Inc. (LPTX) - Yahoo FinanceJuly 5, 2025 | finance.yahoo.comLeap Therapeutics Initiates Process To Explore Strategic OptionsJune 24, 2025 | nasdaq.comLeap Slashes 75% of Workforce, Explores Strategic OptionsJune 24, 2025 | biospace.comBLeap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic AlternativesJune 23, 2025 | prnewswire.comLeap Therapeutics, Inc.: Leap Therapeutics Reports First Quarter 2025 Financial ResultsMay 13, 2025 | finanznachrichten.deLeap halves head count, narrows lead cancer drug's focus amid 'difficult market environment'May 13, 2025 | fiercebiotech.comFLeap Therapeutics Reports First Quarter 2025 Financial ResultsMay 13, 2025 | prnewswire.comLeap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual MeetingApril 25, 2025 | prnewswire.comLeap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal CancerApril 15, 2025 | prnewswire.comLeap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study TranscriptMarch 31, 2025 | seekingalpha.comH.C. Wainwright Reaffirms Their Hold Rating on Leap Therapeutics (LPTX)March 27, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLPTX, DTIL, HLVX, and ATYR Company DescriptionsaTyr Pharma NASDAQ:ATYR$1.02 +0.02 (+2.00%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$1.01 -0.01 (-0.49%) As of 10/17/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.Precision BioSciences NASDAQ:DTIL$6.90 +0.26 (+3.92%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$6.90 0.00 (0.00%) As of 10/17/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.HilleVax NASDAQ:HLVX$2.09 0.00 (0.00%) As of 09/17/2025HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.Leap Therapeutics NASDAQ:LPTX$0.55 -0.02 (-3.74%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$0.57 +0.02 (+2.99%) As of 10/17/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.